SCHEMBL6777182

SCHEMBL6777182

N=C(N)Nc1cccc(C(=O)NCC(=O)NC(CC(=O)O)c2cc3ccccc3o2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.52
ITGB3 P05106 13/20 0.46
ITGB1 P05556 9/20 0.46
ITGAV P06756 9/20 0.46
ITGA5 P08648 9/20 0.46
MDM2 Q00987 5/20 0.46
MDM4 O15151 4/20 0.46
ITGA2B P08514 4/20 0.44
NPC1 O15118 5/20 0.44
RAB9A P51151 5/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
ITGB5 P18084 3/20 0.43
ITGB6 P18564 3/20 0.43
ITGB8 P26012 3/20 0.43
ITGA8 P53708 3/20 0.43
TP53 P04637 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
PKM P14618 2/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7837699 0.88 RAB9A (0.50) RXFP1ITGB3ITGB1ITGAVITGA5
SCHEMBL6777196 0.86 RXFP1 (0.47) RXFP1ITGB3ITGB1ITGAVITGA5
SCHEMBL242674 0.86 ITGB3 (0.55) ITGB3ITGB1ITGAVITGA5MDM2
SCHEMBL6778201 0.85 ITGB3 (0.52) ITGB3ITGB1ITGAVITGA5MDM2
SCHEMBL6776850 0.84 ITGB3 (0.49) ITGB3ITGB1ITGAVITGA5MDM2
SCHEMBL6777994 0.84 ITGB3 (0.45) ITGB3ITGB1ITGAVITGA5MDM2
SCHEMBL6776952 0.82 ITGB3 (0.49) ITGB3ITGB1ITGAVITGA5MDM2
SCHEMBL6782067 0.82 ITGB3 (0.55) ITGB3ITGB1ITGAVITGA5MDM2
SCHEMBL6779116 0.82 ITGB3 (0.51) ITGB3ITGB1ITGAVITGA5MDM2
SCHEMBL7838154 0.82 ITGB3 (0.44) RXFP1ITGB3ITGB1ITGAVITGA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP claimed
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO disclosed